It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery’s range of functionally validated potassium channel cell lines and assays enhance your understanding of compound potency and selectivity. Each study is t ailored to your objectives and supported by our expert team, enabling high-throughput screening, selectivity profiling and lead optimization with confidence.
Voltage-Gated Channels
Kv1.1
Kv2.2
Kv7.1/minK
Kv1.2
Kv3.1
Kv7.2
Kv1.3
Kv3.2
Kv7.2 (W236L)
Kv1.4
Kv3.3
Kv7.2/7.3
Kv1.5
Kv3.4
Kv7.4
Kv1.6
Kv4.3
Kv7.4/7.5
Kv1.7
Kv4.3/kChIP
Kv7.5
Kv1.8
Kv7.1
Kv11.1(hERG)
K2P Channels
TREK-1 (human, mouse, rat)
TASK-3 (human and rat)
TWIK-2
TREK-2 (huma, mouse, rat)
TRESK
THIK-1
TASK-1
TRAAK
TASK-2
TWIK-1
Inward Rectifiers
Kir2.1
Kir2.4
Kir4.1/5.1
Kir2.2
Kir4.1
Calcium Activated
KCa1.1 (BK)
KCa2.2 (SK2)
KCa3.1 (SK4)
KCa2.1 (SK1)
KCa2.3 (SK3)
KCa4.1 (SLACK)
Agonist and Antagonist Mode
Our automated patch clamp assays quantify both channel activation and inhibition across potassium channel families using single-concentration and cumulative addition protocols. These assays deliver precise kinetic and mechanistic data to support structure-activity relationship (SAR) studies and guide lead optimization.
Current-Voltage (IV) Assays
Current-voltage (IV) relationships define key biophysical properties, including activation thresholds, voltage dependence, and recovery kinetics. These high-resolution measurements distinguish direct pore block from gating modulation, providing mechanistic clarity essential for SAR optimization.
Functional Selectivity Across Potassium Channel Subtypes
Subtype-resolved assays sepa rate on-target from off-target activity for both therapeutic and safety-driven studies. High assay reproducibility and Z’ performance confirm the robustness of our automated patch clamp platform for multi-target screening and selectivity panels.
iPSC-Derived Sensory Neurons
RealDRGx TM iPSC -derived sensory neuron assays offer a native human context for translational electrophysiology.
Figure 1: Representative current trace showing KV1.5 inhibition by Quinidine.
Figure 2: KV2.2 IV assays in the presence and absence of Quinidine demonstrate voltage-shifted inhibition kinetics, distinguishing direct pore block from gating effects.
Figure 3: Representative subtype profiling shows KV1.3 selective activation by AUT-1 with clear subtype-specific responses.
Figure 4: Human iPSC-derived neurons confirm native KV function and stability, supporting translational relevance.
BK channels are large conductance potassium channels which are expressed in a broad range of…
Posters
Related Capabilities
We bring together a dynamic blend of new talent and experiences pharmaceutical industry experts from around the world, delivering excellence across each stage of discovery.
Comprehensive ion channel assays and bespoke cell lines deliver high-fidelity screening and safety insights, accelerating hit-to-lead and optimization.
Precise ion channel and transporter insights through tailored electrophysiology studies supporting target validation, hit identification, and lead optimization decisions.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
